Drug Information

Drug General Information
Drug ID
D0M0LC
Former ID
DNC013910
Drug Name
5-(2-(4-fluoro-3-methylphenyl)ethynyl)pyrimidine
Drug Type
Small molecular drug
Indication Discovery agent Investigative [529531]
Formula
C13H9FN2
Canonical SMILES
CC1=C(C=CC(=C1)C#CC2=CN=CN=C2)F
InChI
1S/C13H9FN2/c1-10-6-11(4-5-13(10)14)2-3-12-7-15-9-16-8-12/h4-9H,1H3
InChIKey
DCUICHQOGTUMNS-UHFFFAOYSA-N
PubChem Compound ID
44560630
Target and Pathway
Target(s) Metabotropic glutamate receptor 5 Target Info Inhibitor [529531]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Long-term potentiation
Retrograde endocannabinoid signaling
Glutamatergic synapse
Huntington's disease
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Metabotropic glutamate receptor group III pathway
Metabotropic glutamate receptor group I pathway
Endogenous cannabinoid signaling
Reactome G alpha (q) signalling events
Class C/3 (Metabotropic glutamate/pheromone receptors)
WikiPathways Hypothetical Network for Drug Addiction
GPCRs, Class C Metabotropic glutamate, pheromone
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signaling
References
Ref 529531Bioorg Med Chem Lett. 2008 Jul 15;18(14):4098-101. Epub 2008 May 29.Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold.
Ref 529531Bioorg Med Chem Lett. 2008 Jul 15;18(14):4098-101. Epub 2008 May 29.Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.